MILESTONE SCIENTIFIC INC.

(MLSS)
  Report
Delayed Nyse  -  04:00 2022-08-18 pm EDT
1.030 USD   +1.98%
11:10aMilestone Scientific Starts Sales of CompuFlo Epidural Disposables to UofL Health
MT
08:31aMilestone Scientific Commences Sales of CompuFlo® Epidural Disposables Across Three Departments within UofL Health
AQ
08/16TRANSCRIPT : Milestone Scientific Inc., Q2 2022 Earnings Call, Aug 16, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/12/2022 08/15/2022 08/16/2022 08/17/2022 08/18/2022 Date
1.18(c) 1.22(c) 1(c) 1.01(c) 1.03 Last
40 712 57 538 194 661 87 072 19 383 Volume
+5.36% +3.39% -18.03% +1.00% +1.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 9,26 M - -
Net income 2022 -8,42 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,58x
Yield 2022 -
Sales 2023 11,4 M - -
Net income 2023 -7,20 M - -
Net Debt 2023 - - -
P/E ratio 2023 -10,3x
Yield 2023 -
Capitalization 71,0 M 71,0 M -
Capi. / Sales 2022 7,67x
Capi. / Sales 2023 6,24x
Nbr of Employees 26
Free-Float 74,8%
More Financials
Company
Milestone Scientific Inc. is a biomedical technology company. The Company is engaged in research and development that patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical, dental and cosmetic use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, using The Wand,... 
More about the company
Ratings of Milestone Scientific Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about MILESTONE SCIENTIFIC INC.
11:10aMilestone Scientific Starts Sales of CompuFlo Epidural Disposables to UofL Health
MT
08:31aMilestone Scientific Commences Sales of CompuFlo® Epidural Disposables Across Three Dep..
AQ
08/16TRANSCRIPT : Milestone Scientific Inc., Q2 2022 Earnings Call, Aug 16, 2022
CI
08/16Milestone Scientific Provides Business Update for the Second Quarter of 2022
AQ
08/15MILESTONE SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Milestone Scientific Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/12Milestone Scientific Schedules Second Quarter 2022 Financial Results and Business Updat..
AQ
08/04Milestone Scientific, Clinical Technology Partner Over Distribution of CompuFlo Epidura..
MT
08/04Milestone Scientific Announces Distribution Agreement with Clinical Technology, Inc. fo..
AQ
08/04Milestone Scientific Inc. Announces Distribution Agreement with Clinical Technology, In..
CI
08/02Milestone Scientific Commences Sales of its CompuFlo® Epidural System to the University..
AQ
08/02Milestone Scientific Inc. Commences Sales of its CompuFlo® Epidural System to the Unive..
CI
07/19Milestone Scientific Names Hager & Werken as Exclusive STA Single Tooth Anesthesia Syst..
AQ
07/19Milestone Scientific Names Hager & Werken as Exclusive Sta Single Tooth Anesthesia Syst..
CI
More news
News in other languages on MILESTONE SCIENTIFIC INC.
11:10aMilestone Scientific commence à vendre les dispositifs épiduraux jetables CompuFlo à Uo..
08/15Milestone Scientific Inc. annonce ses résultats pour le deuxième trimestre et les six m..
08/04Milestone Scientific et Clinical Technology s'associent pour la distribution du système..
08/04Milestone Scientific Inc. Annonce un accord de distribution avec Clinical Technology, I..
08/02Milestone Scientific Inc. Commence à vendre son système épidural CompuFlo® à l'Universi..
More news
Analyst Recommendations on MILESTONE SCIENTIFIC INC.
More recommendations
Chart MILESTONE SCIENTIFIC INC.
Duration : Period :
Milestone Scientific Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MILESTONE SCIENTIFIC INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,03 $
Average target price 4,00 $
Spread / Average Target 288%
EPS Revisions
Managers and Directors
Jan Adriaan Haverhals President & Chief Executive Officer
Leslie Bernhard Chairman
Mark Hochman Director-Clinical Affairs, Research & Development
Leonard M. Schiller Independent Director
Michael McGeehan Independent Director
Sector and Competitors